VivoSim Labs (NASDAQ:VIVS – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for VivoSim Labs and OmniAb, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
OmniAb has a consensus target price of $11.50, indicating a potential upside of 146.78%. Given OmniAb’s stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than VivoSim Labs.
Insider & Institutional Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
VivoSim Labs has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Valuation and Earnings
This table compares VivoSim Labs and OmniAb”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $112,000.00 | 21.99 | -$13.84 million | ($4.47) | -0.03 |
| OmniAb | $18.67 million | 36.14 | -$64.78 million | ($0.36) | -12.94 |
VivoSim Labs has higher earnings, but lower revenue than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares VivoSim Labs and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| OmniAb | -115.12% | -16.59% | -14.82% |
Summary
OmniAb beats VivoSim Labs on 11 of the 14 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
